research use only
Cat.No.S8965
| Related Targets | Akt Wnt/beta-catenin HSP PKC ROCK Microtubule Associated Integrin Bcr-Abl Actin FAK |
|---|---|
| Other TACC3 Inhibitors | KHS101 hydrochloride |
|
In vitro |
DMSO
: 71 mg/mL
(200.91 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 353.38 | Formula | C18H19N5O3 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2408648-20-2 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | COC1=CC=C(C=C1)C2=NOC(=C2)NC3=NC(=NC=C3)N4CCOCC4 | ||
| Targets/IC50/Ki |
FGFR3
TACC3
(Cell-free assay) 1.5 nM(Kd)
TACC3
(Cell-free assay) 188 nM
|
|---|---|
| In vitro |
BO-264 significantly decreases centrosomal TACC3 during both mitosis and interphase. This compound displays potent anti-proliferative activity in the NCI- 60 cell line panel compromising nine different cancer types. It significantly inhibits the growth of cells harboring FGFR3-TACC3 fusion, an oncogenic driver in diverse malignancies. |
| In vivo |
BO-264's oral administration significantly impairs tumor growth in immunocompromised and immunocompetent breast and colon cancer mouse models, and increases survival without any major toxicity. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.